No disclosed counterparties: IEX, XYL.
| Stage | IEX | % of rev | XYL | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $952M | 100.00% | $2.2B | 100.00% | XYL ×2.31 |
| Gross profit | $430M | 45.13% | $907M | 41.21% | IEX +3.9pp |
| Operating income | $208M | 21.86% | $385M | 17.49% | IEX +4.4pp |
| Pre-tax income | $193M | 20.25% | $365M | 16.58% | IEX +3.7pp |
| Net income | $144M | 15.13% | $288M | 13.08% | IEX +2.0pp |
| Stage | IEX | XYL | Gap · A − B |
|---|---|---|---|
| Revenue | $952M100.00% | $2.2B100.00% | XYL ×2.31 |
| Gross profit | 45.13%$430M | 41.21%$907M | IEX +3.9pp |
| Operating income | 21.86%$208M | 17.49%$385M | IEX +4.4pp |
| Pre-tax income | 20.25%$193M | 16.58%$365M | IEX +3.7pp |
| Net income |
| 15.13%$144M |
| 13.08%$288M |
| IEX +2.0pp |